Candid Therapeutics is a biotechnology company with a mission to create treatments and therapies for various autoimmune disorders. Aiming to improve therapeutic efficacy, the company uses T-cell engager antibodies to gain a deeper understanding of immunological mechanisms. Candid Therapeutics was founded in 2024 by Kenneth Song and is headquartered in San Diego, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/09/2024 | Series A-1 | $96.78MM | $xx.xx | $660.51MM | Boxer Capital, Fairmount Partners, Fidelity, Foresite Capital, Franklin Templeton, Lifesci Venture Partners, Mirae Asset Capital, Orbimed, Polaris Partners, Qiming Venture Partners, Redmile Group, Samsara Biocapital, Soleus Capital, Tcg Crossover Management, Third Rock Ventures, Two River, Venbio Partners, Venrock, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
96,784,584
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Boxer Capital, Fairmount Partners, Fidelity, Foresite Capital, Franklin Templeton, Lifesci Venture Partners, Mirae Asset Capital, Orbimed, Polaris Partners, Qiming Venture Partners, Redmile Group, Samsara Biocapital, Soleus Capital, Tcg Crossover Management, Third Rock Ventures, Two River, Venbio Partners, Venrock, Vida Ventures
|
||||||
09/09/2024 | Series A-2 | $82.96MM | $xx.xx | $660.51MM | Boxer Capital, Fairmount Partners, Fidelity, Foresite Capital, Franklin Templeton, Lifesci Venture Partners, Mirae Asset Capital, Orbimed, Polaris Partners, Qiming Venture Partners, Redmile Group, Samsara Biocapital, Soleus Capital, Tcg Crossover Management, Third Rock Ventures, Two River, Venbio Partners, Venrock, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
82,958,201
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Boxer Capital, Fairmount Partners, Fidelity, Foresite Capital, Franklin Templeton, Lifesci Venture Partners, Mirae Asset Capital, Orbimed, Polaris Partners, Qiming Venture Partners, Redmile Group, Samsara Biocapital, Soleus Capital, Tcg Crossover Management, Third Rock Ventures, Two River, Venbio Partners, Venrock, Vida Ventures
|
||||||
09/09/2024 | Series B | $190.26MM | $xx.xx | $660.51MM | Boxer Capital, Fairmount Partners, Fidelity, Foresite Capital, Franklin Templeton, Lifesci Venture Partners, Mirae Asset Capital, Orbimed, Polaris Partners, Qiming Venture Partners, Redmile Group, Samsara Biocapital, Soleus Capital, Tcg Crossover Management, Third Rock Ventures, Two River, Venbio Partners, Venrock, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
158,547,679
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Boxer Capital, Fairmount Partners, Fidelity, Foresite Capital, Franklin Templeton, Lifesci Venture Partners, Mirae Asset Capital, Orbimed, Polaris Partners, Qiming Venture Partners, Redmile Group, Samsara Biocapital, Soleus Capital, Tcg Crossover Management, Third Rock Ventures, Two River, Venbio Partners, Venrock, Vida Ventures
|